BR112019023776A2 - método para tratar um câncer do sistema nervoso central (snc) em um sujeito humano, anticorpo ou um fragmento de ligação ao antígeno do mesmo, composição, composição farmacêutica, método para imageamento de um tumor em um sujeito e uso de um anticorpo ou fragmento de ligação ao antígeno do mesmo - Google Patents
método para tratar um câncer do sistema nervoso central (snc) em um sujeito humano, anticorpo ou um fragmento de ligação ao antígeno do mesmo, composição, composição farmacêutica, método para imageamento de um tumor em um sujeito e uso de um anticorpo ou fragmento de ligação ao antígeno do mesmo Download PDFInfo
- Publication number
- BR112019023776A2 BR112019023776A2 BR112019023776-3A BR112019023776A BR112019023776A2 BR 112019023776 A2 BR112019023776 A2 BR 112019023776A2 BR 112019023776 A BR112019023776 A BR 112019023776A BR 112019023776 A2 BR112019023776 A2 BR 112019023776A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- amino acid
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 113
- 239000000427 antigen Substances 0.000 title claims description 203
- 102000036639 antigens Human genes 0.000 title claims description 203
- 108091007433 antigens Proteins 0.000 title claims description 203
- 239000012634 fragment Substances 0.000 title claims description 192
- 238000000034 method Methods 0.000 title claims description 104
- 201000007455 central nervous system cancer Diseases 0.000 title claims description 12
- 238000003384 imaging method Methods 0.000 title claims description 10
- 239000000203 mixture Substances 0.000 title claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 139
- 206010061289 metastatic neoplasm Diseases 0.000 claims abstract description 31
- 238000011282 treatment Methods 0.000 claims description 100
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 91
- 230000004083 survival effect Effects 0.000 claims description 63
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 59
- 201000011510 cancer Diseases 0.000 claims description 59
- 206010029260 Neuroblastoma Diseases 0.000 claims description 58
- 102100038078 CD276 antigen Human genes 0.000 claims description 46
- 230000001225 therapeutic effect Effects 0.000 claims description 33
- 238000007914 intraventricular administration Methods 0.000 claims description 31
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 26
- 230000001394 metastastic effect Effects 0.000 claims description 22
- 230000002285 radioactive effect Effects 0.000 claims description 22
- 239000002738 chelating agent Substances 0.000 claims description 21
- 238000004980 dosimetry Methods 0.000 claims description 20
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 102000048770 human CD276 Human genes 0.000 claims description 16
- 201000001441 melanoma Diseases 0.000 claims description 15
- 230000000306 recurrent effect Effects 0.000 claims description 15
- 206010033128 Ovarian cancer Diseases 0.000 claims description 14
- 208000037819 metastatic cancer Diseases 0.000 claims description 14
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 14
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 12
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 238000001959 radiotherapy Methods 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 9
- 210000004881 tumor cell Anatomy 0.000 claims description 8
- 230000036210 malignancy Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 201000002035 ovary rhabdomyosarcoma Diseases 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 2
- 241001529936 Murinae Species 0.000 claims 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 239000000463 material Substances 0.000 abstract description 8
- 208000007650 Meningeal Carcinomatosis Diseases 0.000 abstract 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 41
- 201000010099 disease Diseases 0.000 description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
- 238000002560 therapeutic procedure Methods 0.000 description 29
- 206010027476 Metastases Diseases 0.000 description 24
- 238000002347 injection Methods 0.000 description 24
- 239000007924 injection Substances 0.000 description 24
- 229960003330 pentetic acid Drugs 0.000 description 23
- 230000000694 effects Effects 0.000 description 19
- 230000009467 reduction Effects 0.000 description 16
- 230000005855 radiation Effects 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 238000003745 diagnosis Methods 0.000 description 14
- 206010065553 Bone marrow failure Diseases 0.000 description 13
- 101710185679 CD276 antigen Proteins 0.000 description 13
- 230000009401 metastasis Effects 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 208000000172 Medulloblastoma Diseases 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000006872 improvement Effects 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 11
- 230000001093 anti-cancer Effects 0.000 description 9
- -1 for example Proteins 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000011363 radioimmunotherapy Methods 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- 108700012912 MYCN Proteins 0.000 description 7
- 101150022024 MYCN gene Proteins 0.000 description 7
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 238000004393 prognosis Methods 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 201000009047 Chordoma Diseases 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 208000037821 progressive disease Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 206010041067 Small cell lung cancer Diseases 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 208000006571 choroid plexus carcinoma Diseases 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 201000009906 Meningitis Diseases 0.000 description 4
- 206010051696 Metastases to meninges Diseases 0.000 description 4
- 206010050487 Pinealoblastoma Diseases 0.000 description 4
- 208000007641 Pinealoma Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 201000003113 pineoblastoma Diseases 0.000 description 4
- 238000002600 positron emission tomography Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229940051022 radioimmunoconjugate Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 description 3
- 201000000582 Retinoblastoma Diseases 0.000 description 3
- 101100537665 Trypanosoma cruzi TOR gene Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 3
- 238000011221 initial treatment Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- PDWUPXJEEYOOTR-UHFFFAOYSA-N 2-[(3-iodophenyl)methyl]guanidine Chemical compound NC(=N)NCC1=CC=CC(I)=C1 PDWUPXJEEYOOTR-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010061819 Disease recurrence Diseases 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 2
- 206010059282 Metastases to central nervous system Diseases 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000008938 Rhabdoid tumor Diseases 0.000 description 2
- 206010073334 Rhabdoid tumour Diseases 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- 231100000987 absorbed dose Toxicity 0.000 description 2
- 238000011374 additional therapy Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000007369 choroid plexus cancer Diseases 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 238000009593 lumbar puncture Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 108091088477 miR-29a stem-loop Proteins 0.000 description 2
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 description 2
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 description 2
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102100027047 Cell division control protein 6 homolog Human genes 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 241000759568 Corixa Species 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 1
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 1
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000914465 Homo sapiens Cell division control protein 6 homolog Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102100038609 Lactoperoxidase Human genes 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010035551 Pleocytosis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000007470 bone biopsy Methods 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 229940119099 cytomel Drugs 0.000 description 1
- 230000002435 cytoreductive effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 208000028919 diffuse intrinsic pontine glioma Diseases 0.000 description 1
- 208000026144 diffuse midline glioma, H3 K27M-mutant Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000008826 genomic mutation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 238000002697 interventional radiology Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PDWUPXJEEYOOTR-IUAIQHPESA-N iobenguane (123I) Chemical compound NC(N)=NCC1=CC=CC([123I])=C1 PDWUPXJEEYOOTR-IUAIQHPESA-N 0.000 description 1
- XMBWDFGMSWQBCA-OIOBTWANSA-N iodane Chemical compound [124IH] XMBWDFGMSWQBCA-OIOBTWANSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 229910021644 lanthanide ion Inorganic materials 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007107 neurocognitive deficit Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- FJWLWIRHZOHPIY-UHFFFAOYSA-N potassium;hydroiodide Chemical compound [K].I FJWLWIRHZOHPIY-UHFFFAOYSA-N 0.000 description 1
- DTBMTXYWRJNBGK-UHFFFAOYSA-L potassium;sodium;phthalate Chemical compound [Na+].[K+].[O-]C(=O)C1=CC=CC=C1C([O-])=O DTBMTXYWRJNBGK-UHFFFAOYSA-L 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000007409 radiographic assessment Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000009601 thyroid function test Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Nuclear Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762505558P | 2017-05-12 | 2017-05-12 | |
| US62/505,558 | 2017-05-12 | ||
| PCT/US2018/032559 WO2018209346A1 (en) | 2017-05-12 | 2018-05-14 | Use of anti-b7h3 antibodies for treating cancer in the central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019023776A2 true BR112019023776A2 (pt) | 2020-07-28 |
Family
ID=64102794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019023776-3A BR112019023776A2 (pt) | 2017-05-12 | 2018-05-14 | método para tratar um câncer do sistema nervoso central (snc) em um sujeito humano, anticorpo ou um fragmento de ligação ao antígeno do mesmo, composição, composição farmacêutica, método para imageamento de um tumor em um sujeito e uso de um anticorpo ou fragmento de ligação ao antígeno do mesmo |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200197546A1 (enExample) |
| EP (1) | EP3635012A4 (enExample) |
| JP (2) | JP2020520382A (enExample) |
| KR (1) | KR20200008580A (enExample) |
| CN (1) | CN110799542A (enExample) |
| AU (1) | AU2018265888A1 (enExample) |
| BR (1) | BR112019023776A2 (enExample) |
| CA (1) | CA3062335A1 (enExample) |
| EA (1) | EA201992683A1 (enExample) |
| RU (1) | RU2019140833A (enExample) |
| WO (1) | WO2018209346A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113853220A (zh) * | 2019-03-11 | 2021-12-28 | 生物相容英国有限公司 | 用于中枢神经系统肿瘤治疗的放射性微球 |
| EP4022313A1 (en) | 2019-08-30 | 2022-07-06 | Y-Mabs Therapeutics, Inc. | Immunohistochemical assessment of b7-h3 expression |
| WO2021190586A1 (zh) * | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | B7h3抗体-依喜替康类似物偶联物及其医药用途 |
| CN117024590A (zh) * | 2020-04-22 | 2023-11-10 | 复星凯特生物科技有限公司 | 抗人b7-h3的单克隆抗体及其应用 |
| EP4138931A1 (en) | 2020-04-24 | 2023-03-01 | Y-Mabs Therapeutics, Inc. | B7h3 antibodies with chelators |
| CN112961241B (zh) * | 2020-06-30 | 2022-04-22 | 广州百暨基因科技有限公司 | 抗b7h3抗体及其应用 |
| WO2022167052A1 (en) * | 2021-02-08 | 2022-08-11 | Y-Mabs Therapeutics, Inc. | Use of ascorbic acid as stabilizing agent for anti b7-h3 antibodies |
| KR20230145038A (ko) | 2021-02-09 | 2023-10-17 | 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 | 생물활성 물질 접합체, 이의 제조방법 및 이의 용도 |
| US20240199750A1 (en) | 2021-03-26 | 2024-06-20 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| KR20240019297A (ko) | 2021-06-09 | 2024-02-14 | 이나뜨 파르마 에스.에이. | Nkp46, 사이토카인 수용체, 종양 항원 및 cd16a 에 결합하는 다중특이적 단백질 |
| US20240392007A1 (en) * | 2021-09-27 | 2024-11-28 | Shenghe (China) Biopharmaceutical Co., Ltd. | Heterodimeric protein and application thereof |
| EP4480499A1 (en) | 2022-02-16 | 2024-12-25 | Medilink Therapeutics (Suzhou) Co., Ltd. | Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof |
| CN119212733A (zh) | 2022-05-18 | 2024-12-27 | 苏州宜联生物医药有限公司 | 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
| WO2024008039A1 (zh) * | 2022-07-08 | 2024-01-11 | 盛禾(中国)生物制药有限公司 | 一种异源二聚体融合蛋白及其应用 |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY133346A (en) * | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| JP2010523478A (ja) * | 2007-03-22 | 2010-07-15 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | モノクローナル抗体８ｈ９の使用 |
| PH12012501751A1 (en) * | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| BR112017003582B1 (pt) * | 2014-08-27 | 2024-01-09 | Memorial Sloan Kettering Cancer Center | Agente de anticorpo, uso do mesmo, composição farmacêutica e receptor de antígeno quimérico |
| WO2016106004A1 (en) * | 2014-12-23 | 2016-06-30 | Full Spectrum Genetics, Inc. | Novel anti-b7h3 binding compounds and uses thereof |
-
2018
- 2018-05-14 EA EA201992683A patent/EA201992683A1/ru unknown
- 2018-05-14 US US16/613,028 patent/US20200197546A1/en not_active Abandoned
- 2018-05-14 JP JP2020513491A patent/JP2020520382A/ja active Pending
- 2018-05-14 CN CN201880040310.2A patent/CN110799542A/zh active Pending
- 2018-05-14 RU RU2019140833A patent/RU2019140833A/ru unknown
- 2018-05-14 EP EP18797639.4A patent/EP3635012A4/en not_active Withdrawn
- 2018-05-14 BR BR112019023776-3A patent/BR112019023776A2/pt unknown
- 2018-05-14 KR KR1020197036884A patent/KR20200008580A/ko not_active Ceased
- 2018-05-14 WO PCT/US2018/032559 patent/WO2018209346A1/en not_active Ceased
- 2018-05-14 CA CA3062335A patent/CA3062335A1/en active Pending
- 2018-05-14 AU AU2018265888A patent/AU2018265888A1/en not_active Abandoned
-
2022
- 2022-12-07 JP JP2022195529A patent/JP2023016969A/ja active Pending
-
2024
- 2024-01-24 US US18/421,157 patent/US20240415990A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200008580A (ko) | 2020-01-28 |
| EA201992683A1 (ru) | 2020-04-23 |
| US20200197546A1 (en) | 2020-06-25 |
| CA3062335A1 (en) | 2018-11-15 |
| US20240415990A1 (en) | 2024-12-19 |
| JP2023016969A (ja) | 2023-02-02 |
| JP2020520382A (ja) | 2020-07-09 |
| RU2019140833A (ru) | 2021-06-15 |
| AU2018265888A1 (en) | 2019-11-21 |
| EP3635012A1 (en) | 2020-04-15 |
| CN110799542A (zh) | 2020-02-14 |
| RU2019140833A3 (enExample) | 2022-02-07 |
| WO2018209346A1 (en) | 2018-11-15 |
| EP3635012A4 (en) | 2020-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240415990A1 (en) | Use of anti-b7h3 antibodies for treating cancer in the central nervous system | |
| Adams et al. | A Single Treatment of Yttrium-90-labeled CHX-A ″–C6. 5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient Mice | |
| Kramer et al. | Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma | |
| JP7274646B2 (ja) | 血液悪性疾患を処置するための低用量抗体に基づく方法 | |
| Foster et al. | Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma | |
| Reardon et al. | Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients | |
| Bartholomä | Radioimmunotherapy of solid tumors: approaches on the verge of clinical application | |
| Fiedler et al. | Evaluation of 177Lu [Lu]-CHX-A ″-DTPA-6A10 Fab as a radioimmunotherapy agent targeting carbonic anhydrase XII | |
| AU2016268038A1 (en) | Systems and methods for determining optimum patient-specific antibody dose for tumor targeting | |
| Bailey et al. | Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes | |
| Ehlerding et al. | Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody | |
| Witzig et al. | Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma | |
| Wei et al. | Engineered antibodies as cancer radiotheranostics | |
| Kondo et al. | [225Ac] Ac-and [111In] In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts | |
| Kameswaran et al. | Preparation and preclinical evaluation of 131I‐trastuzumab for breast cancer | |
| Tuazon et al. | Yttrium-90 anti-CD45 immunotherapy followed by autologous hematopoietic cell transplantation for relapsed or refractory lymphoma | |
| Takashima et al. | Tumor targeting of 211At-labeled antibody under sodium ascorbate protection against radiolysis | |
| Sugyo et al. | Anti-tissue factor antibody-mediated immuno-SPECT imaging of tissue factor expression in mouse models of pancreatic cancer | |
| Eriksson et al. | Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb | |
| Kemshead et al. | Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies | |
| AU2006242245B2 (en) | Combination therapy in the treatment of cancer | |
| Yang et al. | 89Zr and 177Lu labeling of anti-DR5 monoclonal antibody for colorectal cancer targeting PET-imaging and radiotherapy | |
| KR20200103751A (ko) | 센트린-1에 대한 항체, 이의 제조 방법, 및 용도 | |
| CN117813326A (zh) | 基于放射的导蛋白-1的检测、伴随测试和治疗方法 | |
| Salouti et al. | Comparison of 99mTc-labeled PR81 and its F (ab′) 2 fragments as radioimmunoscintigraphy agents for breast cancer imaging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |